Daniel C. Martin - 18 Jan 2022 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc.

Role: Chief Commercial Officer
Signature: /s/ Jeffrey Held, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 18 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 20 Jan 2022, 16:00:34 UTC
Previous filing: 17 Dec 2021
Next filing: 18 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DCPH	Common Stock	Award	$0	+13,667	+38%	$0.000000	49,814	18 Jan 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DCPH	Stock Option (Right to Buy)	Award	$0	+54,667		$0.000000	54,667	18 Jan 2022	Common Stock	54,667	$8.27	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person was awarded 13,667 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock. The RSUs shall vest in three (3) equal annual installments on each of January 15, 2023, January 15, 2024 and January 15, 2025.
F2	This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four (4) years, beginning on February 18, 2022.